Compare · MMM vs TTOO
MMM vs TTOO
Side-by-side comparison of 3M Company (MMM) and T2 Biosystems Inc. (TTOO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and TTOO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $80.20B, about 1283.1x TTOO ($62.5M).
- MMM has hit the wire 2 times in the past 4 weeks while TTOO has been quiet.
- MMM has more recent analyst coverage (25 ratings vs 1 for TTOO).
- Company
- 3M Company
- T2 Biosystems Inc.
- Price
- $153.78+0.65%
- $0.13-34.35%
- Market cap
- $80.20B
- $62.5M
- 1M return
- +4.91%
- -
- 1Y return
- +6.64%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 2
- 0
- Recent ratings
- 25
- 1
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
T2 Biosystems Inc.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest MMM
- SEC Form SD filed by 3M Company
- 3M Announces Upcoming Investor Event
- 3M Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Sweet Thomas W was granted 1,360 shares (SEC Form 4)
- Director Kereere Suzan was granted 1,360 shares, increasing direct ownership by 27% to 6,422 units (SEC Form 4)
- Director Fitterling James R was granted 1,360 shares (SEC Form 4)
- Director Brown Thomas K was granted 1,360 shares (SEC Form 4)
- Director Chow Anne H was granted 1,360 shares (SEC Form 4)
- Director Choi Audrey was granted 1,360 shares (SEC Form 4)
- Director Bozeman David P was granted 1,360 shares (SEC Form 4)
Latest TTOO
- Amendment: SEC Form 25-NSE/A filed by T2 Biosystems Inc.
- SEC Form 25-NSE filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.
- SEC Form NT 10-K filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.
- T2 Biosystems Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities
- Amendment: SEC Form SCHEDULE 13G/A filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.
- SEC Form DEF 14A filed by T2 Biosystems Inc.
- SEC Form 8-K filed by T2 Biosystems Inc.